Intellia Therapeutics Inc (NTLA) stock news · rev $67.7M
Intellia Therapeutics Inc (NTLA) is a biotechnology company listed on US.
This NTLA news page leads with what Intellia Therapeutics Inc filed — not a scraped headline mill.
No cached 8-K sentence for NTLA yet. We will not pad this page with generic market recap.
Latest reported NTLA revenue for 2025-12-31 was $67.7M. Net income was -$412.7M. Revenue was up 16.9% from 2024-12-31 to 2025-12-31. NTLA currently screens at market cap $1.19B.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the NTLA stock page; for the tape open the quote page.
NTLA stock news FAQ
What are NTLA's latest revenue and net income?
Latest cached Intellia Therapeutics Inc (NTLA) revenue for Dec 31, 2025 was $67.7M. Net income was -$412.7M. Statements: https://lician.com/financials/ntla
How did NTLA revenue change from the prior cached period?
Cached Intellia Therapeutics Inc (NTLA) revenue was up 16.9% from $57.9M (Dec 31, 2024) to $67.7M (Dec 31, 2025). Statements: https://lician.com/financials/ntla
What is NTLA's market cap?
Intellia Therapeutics Inc (NTLA) market cap is $1.19B on the latest cached fundamentals snapshot.
What kind of company is NTLA?
Intellia Therapeutics Inc (NTLA) is a biotechnology company listed on US.
Where is NTLA stock news listed?
Cached stock news for Intellia Therapeutics Inc (NTLA) is listed at https://lician.com/news/ntla. Filings: https://lician.com/sec/ntla
Not investment advice.